STOCK TITAN
  1. Home
  2. Sec-filings
  3. ABOS
  4. [EFFECT] Acumen Pharmaceuticals, Inc. SEC Filing

[EFFECT] Acumen Pharmaceuticals, Inc. SEC Filing

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
EFFECT
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Notice of Effectiveness
Effectiveness Date: April 1, 2026 4:00 P.M.
Form: S-3
CIK: 0001576885
Company Name: Acumen Pharmaceuticals, Inc.
File Number: 333-294649

Source: View Original Filing on SEC EDGAR

Acumen Pharmaceuticals, Inc.

NASDAQ:ABOS

View ABOS Stock Overview →

ABOS Rankings

#4570 Ranked by Market Cap
N/A Ranked by Dividends

ABOS Latest News

Mar 26, 2026
Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2025 and Business Highlights
Mar 19, 2026
Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2025 Financial Results on March 26, 2026
Mar 17, 2026
Acumen Pharmaceuticals Presents Studies on Enhanced Brain Delivery™, Biomarker Research, and Novel Antibodies at Advances in Alzheimer's Treatment at International Conference on Alzheimer’s and Parkinson’s Diseases 2026
Mar 16, 2026
Acumen Pharmaceuticals Announces $35.75 Million Private Placement to Advance Potential Best-in-Class Molecules from Amyloid Beta Oligomer-Selective Enhanced Brain Delivery Portfolio
Mar 10, 2026
Acumen Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum

ABOS Latest SEC Filings

Apr 1, 2026
[424B3] Acumen Pharmaceuticals, Inc. Prospectus Filed Pursuant to Rule 424(b)(3)
Mar 26, 2026
[S-3] Acumen Pharmaceuticals, Inc. Shelf Registration Statement
Mar 26, 2026
[10-K] Acumen Pharmaceuticals, Inc. Files Annual Report
Mar 26, 2026
[8-K] Acumen Pharmaceuticals, Inc. Reports Material Event
Mar 18, 2026
[Form 4] Acumen Pharmaceuticals, Inc. Insider Trading Activity

ABOS Stock Data

184.14M
55.45M
Biotechnology
Biological Products, (no Diagnostic Substances)
Link
United States
NEWTON